According to Future Market Insights (FMI) analysis in a recent market survey, the global cervical cancer screening market was valued at US$ 1.4 Billion in 2022 and is expected to reach US$ 5.7 Billion by 2033.
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | US$ 1.4 Billion |
| Market Value 2023 | US$ 1.6 Billion |
| Market Value 2033 | US$ 5.7 Billion |
| CAGR 2023 to 2033 | 13.7% |
| Share of Top 5 Countries | 50.2% |
| Key Players | The key players in the cervical cancer screening market are Abbott Laboratories, Becton, Dickinson and Company, F. Hoffmann-La Roche, Hologic, Inc., QIAGEN, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., Promega Corporation, Sysmex Inostics Inc., Danaher (Cepheid), FUJIREBIO, Everlywell, Inc., and Sansure Biotech Inc. |
Cervical screening encompasses various methods such as cervical cytology (Pap test or Pap smear), human papillomavirus (HPV) testing, or a combination of both. It is recommended that most women undergo routine cervical cancer screening to ensure early detection and appropriate preventive measures. A Pap test can occasionally reveal diseases like inflammation or infection that are not malignancy. The HPV/Pap co-test examines cervical cell alterations as well as high-risk HPV using both an HPV test and a Pap test.
Overall, the increasing screening for the detection of cervical cancer will boost the market in the coming years.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Sales of the cervical cancer screening market grew at a CAGR of 7.4% from 2012 to 2022. The cervical cancer screening market contributes a 0.7% revenue share to the global cancer diagnostics market in 2022 which was valued at US$ 191.0 Billion.
About 70% of cervical cancer occurrences globally are caused by HPV strains 16 and 18. It is now possible to prevent HPV 16 and 18 infections, which has the potential to lower the prevalence of anogenital and cervical malignancies. Squamous intraepithelial lesion (SIL) and cervical intraepithelial neoplasia (CIN) are widely used terms to describe the presence of abnormal squamous cell growth in the cervix, indicating a precancerous condition.
On 4th March 2023, International Agency for Research on Cancer mentioned that more than 300 000 women per year die from cervical cancer, which is currently the fourth most prevalent cancer in women. In low- and middle-income nations, cervical cancer fatalities account for almost 90% of all deaths.
Other than the Pap test and HPV test, in low-resource situations, visual examination with acetic acid (VIA) can replace cytology-based screening.
Considering this, FMI expects the global cervical cancer screening market to grow at a CAGR of 13.7% through the forecasted years.
The objective of cervical cancer screening is to identify precancerous changes in cervical cells that can be effectively treated to prevent the progression of cervical cancer.
New advancements in human papillomavirus (HPV) DNA testing, Papanicolaou test technology, and updates to the Bethesda terminology for cervical cytology have led to changes in the management of abnormal Pap tests. A recent clinical trial has provided information that includes a reduction in the number of colposcopies required by 50% in certain cases. Femtech is driving a significant transformation in women's healthcare.
Leading manufacturers are focusing on affordable testing and also reducing the overall cost of treatment with the help of technologically advanced screening tests. This creates an opportunity for the market to expand exponentially.
Principal Consultant
The Pap test is a crucial element of a woman's overall health. It assists in the early detection of cervix precancerous cells before they transform into malignant cells. However, the Pap test has some limitations as a cervical cancer prevention method.
Traditional cervical cancer screening methods primarily focus on examining the end cervical canal. Patients often undergo an invasive procedure called a colposcopy when an abnormal Pap screening is observed. This involves visualizing cervical cancer and collecting tissue samples. However, for many years, the only available instruments for tissue collection were conventional ones such as brushes or a Kevorkian curette.
The Pap test's primary flaw is that, like many other tests, it is unable to provide accurate results. In the event that a Pap test yields a false positive result, the cervix may contain precancerous cells.
The USA dominated the global market with a value share of around 25.1% in 2022.
The American College of Obstetricians and Gynecologists (ACOG), the American Society for Colposcopy and Cervical Pathology (ASCCP), and the Society of Gynecologic Oncologists SGO nonetheless advise starting cervical cancer screening at age 21. Obstetricians-gynecologists and other healthcare practitioners should continue to strongly advise eligible people to get the HPV vaccine and emphasize its advantages and safety as another key method of preventing cervical cancer.
The demand for cervical cancer screening will increase with the assistance of awareness created by the established player and create an area for diagnostics testing labs to provide low-cost health checkups, which will drive the expansion of the market.
Japan is projected to be the most attractive market in cervical cancer screening and holds a market share of 7.6% in the global market in 2022. The Japanese government is working actively for the benefit of women’s welfare.
Germany dominated the global market for cervical cancer screening and accounted for 6.3% of the market share in 2022.
Germany conducted a screening program for the prevention of cervical cancer in women from the age of 35 years with the collaboration of Statutory Health Insurance (GKV) to understand the dynamics of cervical cancer screening. A groundbreaking implementation of HPV co-testing and cytology in a substantial population of women aged 35 and above in Germany suggests that this approach could enhance cervical cancer prevention, particularly when combined with liquid-based computer-assisted cytology examinations that incorporate patients' HPV status.
The presence of prominent players in Germany will influence the overall market.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The human papillomavirus (HPV) segment held the major chunk of 75.0% of the global market by the end of 2022.
The main factor causing cervical cancer is HPV. The majority of occurrences of cervical cancer are caused by high-risk HPV strains like HPV 16 and 18, which account for about 70% of cases, as per WHO 2022 insights.
Overall, human papillomavirus (HPV) is a widely adopted test that helps in screening for cervical cancer.
Squamous cell carcinomas were the predominant segment with a market share of 57.5% in the global market by the end of 2022.
As per the Cancer Research UK 2020 statistics, nearly 70% to 90% of all occurrences of cervical cancer are squamous cell carcinoma, making it the most prevalent kind. The squamous cells that border the outside of the cervix give rise to this type of cancer.
As it is the predominant occurring cervical cancer it holds the highest market share in the global market.
The 31 - 65 years age group accounted for a revenue share of 61.7% in the global market at the end of 2022.
The human papillomavirus (HPV), particularly HPV types 16 and 18 often acquired during sexual activity. The virus is often cleared by the immune system within a couple of years, but occasionally the infection lingers and raises the risk of cervical cancer.
Between the ages of 31 and 65, those who contracted HPV may start to feel the effects of a persistent infection, which can result in the development of cervical cancer. Hence ages of 31 and 65 hold a significant share of the global market.
The hospital segment accounted for a revenue share of 39.7% in the global market at the end of 2022.
Hospitals typically have specialized departments or clinics dedicated to women's health, including cervical cancer screening. These facilities ensure that the testing is conducted in a controlled and efficient manner.
Overall, hospitals offer a setting that encourages interaction between healthcare practitioners with various expertise, making it the lucrative segment of end users.
Among the primary approaches used by manufacturers to get a competitive edge in the market are pricing strategies, market strategies, technical advancements, regulatory compliance, and acquisition and distribution agreements with other businesses to expand their business.
For instance:
Similarly, recent developments have been tracked by the team at Future Market Insights related to companies in cervical cancer screening market space, which are available in the full report
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2012 to 2022 |
| Market Analysis | USD Million for Value |
| Key Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East; and Africa (MEA) |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, Germany, UK, France, Italy, Spain, Russia, BENELUX, Nordics, China, Japan, South Korea, India, Thailand, Indonesia, Malaysia, Australia, New Zealand, Türkiye, South Africa, North Africa, and GCC Countries |
| Key Segments Covered | Test, Cancer, Age Group, End User, and Region |
| Key Companies Profiled | Abbott Laboratories; Becton, Dickinson, and Company; F. Hoffmann-La Roche; Hologic, Inc.; QIAGEN; Bio-Rad Laboratories, Inc.; Thermo Fisher Scientific Inc.; Promega Corporation; Sysmex Inostics Inc.; Danaher (Cepheid); FUJIREBIO; Everlywell, Inc.; Sansure Biotech Inc. |
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
The hospital holds high revenue potential.
The United States, Japan, and Germany are advancing in healthcare.
The market is forecast to register a CAGR of 13.7% through 2033.
During 2018 to 2022, the market registered a CAGR of 7.4%.
The popularity of new advanced test technologies increases current market trends.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusion and Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Test Innovation/ Development Trends 4. Value-Added Insights 4.1. Epidemiology of Cervical Cancer 4.2. Distribution Channel Analysis 4.3. Regulatory Scenario 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global GDP Growth Outlook 5.1.2. Global Healthcare Expenditure Outlook 5.1.3. Global Cancer Diagnostics Market Outlook 5.2. Forecast Factors - Relevance & Impact 5.2.1. Cervical Cancer Epidemiology 5.2.2. Regulatory Framework 5.2.3. Recent Advancements In Technology 5.2.4. Clinical, and Economic Impacts 5.2.5. New Product Launches and Development 5.2.6. Top Companies Historic Growth 5.2.7. Increasing Rate of Screening Adoption 5.2.8. Government Funding 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. COVID-19 Crisis Analysis 6.1. 2022 Market Scenario 6.2. COVID-19 and Impact Analysis 6.2.1. By Test 6.2.2. By Cancer 6.2.3. By End User 6.2.4. By Age Group 6.2.5. By Region 7. Global Market Demand (in Value or Size in US$ Mn) Analysis 2012 to 2022 and Forecast, 2023 to 2033 7.1. Historical Market Value (US$ Million) Analysis, 2012 to 2022 7.2. Current and Future Market Value (US$ Million) Projections, 2023 to 2033 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Test 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Million) Analysis by Test, 2012 to 2022 8.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Test, 2023 to 2033 8.3.1. Cervical Cytology (Pap smear) 8.3.2. Human Papillomavirus (HPV) 8.3.3. Visual inspection with acetic acid (VIA) 8.4. Market Attractiveness Analysis by Test 9. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Cancer 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Million) Analysis by Cancer, 2012 to 2022 9.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Cancer, 2023 to 2033 9.3.1. Squamous Cell Carcinomas 9.3.2. Adenocarcinomas 9.4. Market Attractiveness Analysis by Cancer 10. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Age Group 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Million) Analysis by Age Group, 2012 to 2022 10.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Age Group, 2023 to 2033 10.3.1. 21 - 30 Years 10.3.2. 31 - 65 Years 10.4. Market Attractiveness Analysis by Age Group 11. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By End User 11.1. Introduction / Key Findings 11.2. Historical Market Size (US$ Million) Analysis by End User, 2012 to 2022 11.3. Current and Future Market Size (US$ Million) Analysis and Forecast by End User, 2023 to 2033 11.3.1. Hospitals 11.3.2. Cancer Research Institutes 11.3.3. Specialty Clinics 11.3.4. Diagnostic Laboratories 11.4. Market Attractiveness Analysis by End User 12. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Region 12.1. Introduction 12.2. Historical Market Size (US$ Million) Analysis by Region, 2012 to 2022 12.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Region, 2023 to 2033 12.3.1. North America 12.3.2. Latin America 12.3.3. Europe 12.3.4. East Asia 12.3.5. South Asia 12.3.6. Oceania 12.3.7. Middle East and Africa 12.4. Market Attractiveness Analysis by Region 13. North America Market Analysis 2012 to 2022 and Forecast 2023 to 2033 13.1. Introduction 13.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2012 to 2022 13.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 13.3.1. By Country 13.3.1.1. United States of America 13.3.1.2. Canada 13.3.2. By Test 13.3.3. By Cancer 13.3.4. By End User 13.3.5. By Age Group 13.4. Market Attractiveness Analysis 13.4.1. By Country 13.4.2. By Test 13.4.3. By Cancer 13.4.4. By End User 13.4.5. By Age Group 13.5. Market Trends 13.6. Key Market Participants - Intensity Mapping 13.7. Drivers and Restraints - Impact Analysis 13.8. Country-Level Analysis & Forecast 13.8.1. United States of America Market 13.8.1.1. Introduction 13.8.1.2. Market Analysis and Forecast by Market Taxonomy 13.8.1.2.1. By Test 13.8.1.2.2. By Cancer 13.8.1.2.3. By End User 13.8.1.2.4. By Age Group 13.8.2. Canada Market 13.8.2.1. Introduction 13.8.2.2. Market Analysis and Forecast by Market Taxonomy 13.8.2.2.1. By Test 13.8.2.2.2. By Cancer 13.8.2.2.3. By End User 13.8.2.2.4. By Age Group 14. Latin America Market Analysis 2012 to 2022 and Forecast 2023 to 2033 14.1. Introduction 14.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2012 to 2022 14.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 14.3.1. By Country 14.3.1.1. Mexico 14.3.1.2. Brazil 14.3.1.3. Argentina 14.3.1.4. Rest of Latin America 14.3.2. By Test 14.3.3. By Cancer 14.3.4. By End User 14.3.5. By Age Group 14.4. Market Attractiveness Analysis 14.4.1. By Country 14.4.2. By Test 14.4.3. By Cancer 14.4.4. By End User 14.4.5. By Age Group 14.5. Market Trends 14.6. Key Market Participants - Intensity Mapping 14.7. Drivers and Restraints - Impact Analysis 14.8. Country-Level Analysis & Forecast 14.8.1. Mexico Market 14.8.1.1. Introduction 14.8.1.2. Market Analysis and Forecast by Market Taxonomy 14.8.1.2.1. By Test 14.8.1.2.2. By Cancer 14.8.1.2.3. By End User 14.8.1.2.4. By Age Group 14.8.2. Brazil Market 14.8.2.1. Introduction 14.8.2.2. Market Analysis and Forecast by Market Taxonomy 14.8.2.2.1. By Test 14.8.2.2.2. By Cancer 14.8.2.2.3. By End User 14.8.2.2.4. By Age Group 14.8.3. Argentina Market 14.8.3.1. Introduction 14.8.3.2. Market Analysis and Forecast by Market Taxonomy 14.8.3.2.1. By Test 14.8.3.2.2. By Cancer 14.8.3.2.3. By End User 14.8.3.2.4. By Age Group 15. Europe Market Analysis 2012 to 2022 and Forecast 2023 to 2033 15.1. Introduction 15.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2012 to 2022 15.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 15.3.1. By Country 15.3.1.1. United Kingdom 15.3.1.2. Germany 15.3.1.3. Italy 15.3.1.4. France 15.3.1.5. Spain 15.3.1.6. Russia 15.3.1.7. BENELUX 15.3.1.8. Rest of Europe 15.3.2. By Test 15.3.3. By Cancer 15.3.4. By End User 15.3.5. By Age Group 15.4. Market Attractiveness Analysis 15.4.1. By Country 15.4.2. By Test 15.4.3. By Cancer 15.4.4. By End User 15.4.5. By Age Group 15.5. Market Trends 15.6. Key Market Participants - Intensity Mapping 15.7. Drivers and Restraints - Impact Analysis 15.8. Country-Level Analysis & Forecast 15.8.1. United Kingdom Market 15.8.1.1. Introduction 15.8.1.2. Market Analysis and Forecast by Market Taxonomy 15.8.1.2.1. By Test 15.8.1.2.2. By Cancer 15.8.1.2.3. By End User 15.8.1.2.4. By Age Group 15.8.2. Germany Market 15.8.2.1. Introduction 15.8.2.2. Market Analysis and Forecast by Market Taxonomy 15.8.2.2.1. By Test 15.8.2.2.2. By Cancer 15.8.2.2.3. By End User 15.8.2.2.4. By Age Group 15.8.3. Italy Market 15.8.3.1. Introduction 15.8.3.2. Market Analysis and Forecast by Market Taxonomy 15.8.3.2.1. By Test 15.8.3.2.2. By Cancer 15.8.3.2.3. By End User 15.8.3.2.4. By Age Group 15.8.4. France Market 15.8.4.1. Introduction 15.8.4.2. Market Analysis and Forecast by Market Taxonomy 15.8.4.2.1. By Test 15.8.4.2.2. By Cancer 15.8.4.2.3. By End User 15.8.4.2.4. By Age Group 15.8.5. Spain Market 15.8.5.1. Introduction 15.8.5.2. Market Analysis and Forecast by Market Taxonomy 15.8.5.2.1. By Test 15.8.5.2.2. By Cancer 15.8.5.2.3. By End User 15.8.5.2.4. By Age Group 15.8.6. Russia Market 15.8.6.1. Introduction 15.8.6.2. Market Analysis and Forecast by Market Taxonomy 15.8.6.2.1. By Test 15.8.6.2.2. By Cancer 15.8.6.2.3. By End User 15.8.6.2.4. By Age Group 15.8.7. BENELUX Market 15.8.7.1. Introduction 15.8.7.2. Market Analysis and Forecast by Market Taxonomy 15.8.7.2.1. By Test 15.8.7.2.2. By Cancer 15.8.7.2.3. By End User 15.8.7.2.4. By Age Group 16. East Asia Market Analysis 2012 to 2022 and Forecast 2023 to 2033 16.1. Introduction 16.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2012 to 2022 16.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 16.3.1. By Country 16.3.1.1. China 16.3.1.2. Japan 16.3.1.3. South Korea 16.3.2. By Test 16.3.3. By Cancer 16.3.4. By Age Group 16.3.5. By End User 16.4. Market Attractiveness Analysis 16.4.1. By Country 16.4.2. By Test 16.4.3. By Cancer 16.4.4. By End User 16.4.5. By Age Group 16.5. Market Trends 16.6. Key Market Participants - Intensity Mapping 16.7. Drivers and Restraints - Impact Analysis 16.8. Country-Level Analysis & Forecast 16.8.1. China Market 16.8.1.1. Introduction 16.8.1.2. Market Analysis and Forecast by Market Taxonomy 16.8.1.2.1. By Test 16.8.1.2.2. By Cancer 16.8.1.2.3. By End User 16.8.1.2.4. By Age Group 16.8.2. Japan Market 16.8.2.1. Introduction 16.8.2.2. Market Analysis and Forecast by Market Taxonomy 16.8.2.2.1. By Test 16.8.2.2.2. By Cancer 16.8.2.2.3. By End User 16.8.2.2.4. By Age Group 16.8.3. South Korea Market 16.8.3.1. Introduction 16.8.3.2. Market Analysis and Forecast by Market Taxonomy 16.8.3.2.1. By Test 16.8.3.2.2. By Cancer 16.8.3.2.3. By End User 16.8.3.2.4. By Age Group 17. South Asia Market Analysis 2012 to 2022 and Forecast 2023 to 2033 17.1. Introduction 17.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2012 to 2022 17.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 17.3.1. By Country 17.3.1.1. India 17.3.1.2. Indonesia 17.3.1.3. Malaysia 17.3.1.4. Thailand 17.3.1.5. Rest of South Asia 17.3.2. By Test 17.3.3. By Cancer 17.3.4. By End User 17.3.5. By Age Group 17.4. Market Attractiveness Analysis 17.4.1. By Country 17.4.2. By Test 17.4.3. By Cancer 17.4.4. By End User 17.4.5. By Age Group 17.5. Market Trends 17.6. Key Market Participants - Intensity Mapping 17.7. Drivers and Restraints - Impact Analysis 17.8. Country-Level Analysis & Forecast 17.8.1. India Market 17.8.1.1. Introduction 17.8.1.2. Market Analysis and Forecast by Market Taxonomy 17.8.1.2.1. By Test 17.8.1.2.2. By Cancer 17.8.1.2.3. By End User 17.8.1.2.4. By Age Group 17.8.2. Indonesia Market 17.8.2.1. Introduction 17.8.2.2. Market Analysis and Forecast by Market Taxonomy 17.8.2.2.1. By Test 17.8.2.2.2. By Cancer 17.8.2.2.3. By End User 17.8.2.2.4. By Age Group 17.8.3. Malaysia Market 17.8.3.1. Introduction 17.8.3.2. Market Analysis and Forecast by Market Taxonomy 17.8.3.2.1. By Test 17.8.3.2.2. By Cancer 17.8.3.2.3. By End User 17.8.3.2.4. By Age Group 17.8.4. Thailand Market 17.8.4.1. Introduction 17.8.4.2. Market Analysis and Forecast by Market Taxonomy 17.8.4.2.1. By Test 17.8.4.2.2. By Cancer 17.8.4.2.3. By End User 17.8.4.2.4. By Age Group 18. Oceania Market Analysis 2012 to 2022 and Forecast 2023 to 2033 18.1. Introduction 18.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2012 to 2022 18.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 18.3.1. By Country 18.3.1.1. Australia 18.3.1.2. New Zealand 18.3.2. By Test 18.3.3. By Cancer 18.3.4. By End User 18.3.5. By Age Group 18.4. Market Attractiveness Analysis 18.4.1. By Country 18.4.2. By Test 18.4.3. By Cancer 18.4.4. By End User 18.4.5. By Age Group 18.5. Market Trends 18.6. Key Market Participants - Intensity Mapping 18.7. Drivers and Restraints - Impact Analysis 18.8. Country-Level Analysis & Forecast 18.8.1. Australia Market 18.8.1.1. Introduction 18.8.1.2. Market Analysis and Forecast by Market Taxonomy 18.8.1.2.1. By Test 18.8.1.2.2. By Cancer 18.8.1.2.3. By End User 18.8.1.2.4. By Age Group 18.8.2. New Zealand Market 18.8.2.1. Introduction 18.8.2.2. Market Analysis and Forecast by Market Taxonomy 18.8.2.2.1. By Test 18.8.2.2.2. By Cancer 18.8.2.2.3. By End User 18.8.2.2.4. By Age Group 19. Middle East and Africa (Middle East and Africa) Market Analysis 2012 to 2022 and Forecast 2023 to 2033 19.1. Introduction 19.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2012 to 2022 19.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 19.3.1. By Country 19.3.1.1. GCC Countries 19.3.1.2. Türkiye 19.3.1.3. South Africa 19.3.1.4. North Africa 19.3.1.5. Rest of Middle East and Africa 19.3.2. By Test 19.3.3. By Cancer 19.3.4. By End User 19.3.5. By Age Group 19.4. Market Attractiveness Analysis 19.4.1. By Country 19.4.2. By Test 19.4.3. By Cancer 19.4.4. By End User 19.4.5. By Age Group 19.5. Market Trends 19.6. Key Market Participants - Intensity Mapping 19.7. Drivers and Restraints - Impact Analysis 19.8. Country-Level Analysis & Forecast 19.8.1. GCC Countries Market 19.8.1.1. Introduction 19.8.1.2. Market Analysis and Forecast by Market Taxonomy 19.8.1.2.1. By Test 19.8.1.2.2. By Cancer 19.8.1.2.3. By End User 19.8.1.2.4. By Age Group 19.8.2. Türkiye Market 19.8.2.1. Introduction 19.8.2.2. Market Analysis and Forecast by Market Taxonomy 19.8.2.2.1. By Test 19.8.2.2.2. By Cancer 19.8.2.2.3. By End User 19.8.2.2.4. By Age Group 19.8.3. South Africa Market 19.8.3.1. Introduction 19.8.3.2. Market Analysis and Forecast by Market Taxonomy 19.8.3.2.1. By Test 19.8.3.2.2. By Cancer 19.8.3.2.3. By End User 19.8.3.2.4. By Age Group 19.8.4. North Africa Market 19.8.4.1. Introduction 19.8.4.2. Market Analysis and Forecast by Market Taxonomy 19.8.4.2.1. By Test 19.8.4.2.2. By Cancer 19.8.4.2.3. By End User 19.8.4.2.4. By Age Group 20. Market Structure Analysis 20.1. Market Analysis by Tier of Companies 20.2. Market Share Analysis of Top Players 20.3. Market Concentration 20.4. Market Presence Analysis 20.4.1. Regional Footprint of Players 20.4.2. Product Footprint by Players 20.4.3. Channel Footprint by Players 21. Competition Analysis 21.1. Competition Dashboard 21.2. Competition Deep Dive 21.2.1. Abbott Laboratories 21.2.1.1. Overview 21.2.1.2. Product Portfolio 21.2.1.3. Key Financials 21.2.1.4. Sales Footprint 21.2.1.5. SWOT Analysis 21.2.1.6. Key Developments 21.2.1.7. Strategy Overview 21.2.1.7.1. Channel Strategy 21.2.1.7.2. Marketing Strategy 21.2.1.7.3. Product Strategy 21.2.2. Becton, Dickinson, and Company, 21.2.2.1. Overview 21.2.2.2. Product Portfolio 21.2.2.3. Key Financials 21.2.2.4. Sales Footprint 21.2.2.5. SWOT Analysis 21.2.2.6. Key Developments 21.2.2.7. Strategy Overview 21.2.2.7.1. Channel Strategy 21.2.2.7.2. Marketing Strategy 21.2.2.7.3. Product Strategy 21.2.3. F. Hoffmann-La Roche 21.2.3.1. Overview 21.2.3.2. Product Portfolio 21.2.3.3. Key Financials 21.2.3.4. Sales Footprint 21.2.3.5. SWOT Analysis 21.2.3.6. Key Developments 21.2.3.7. Strategy Overview 21.2.3.7.1. Channel Strategy 21.2.3.7.2. Marketing Strategy 21.2.3.7.3. Product Strategy 21.2.4. Hologic, Inc. 21.2.4.1. Overview 21.2.4.2. Product Portfolio 21.2.4.3. Key Financials 21.2.4.4. Sales Footprint 21.2.4.5. SWOT Analysis 21.2.4.6. Key Developments 21.2.4.7. Strategy Overview 21.2.4.7.1. Channel Strategy 21.2.4.7.2. Marketing Strategy 21.2.4.7.3. Product Strategy 21.2.5. QIAGEN 21.2.5.1. Overview 21.2.5.2. Product Portfolio 21.2.5.3. Key Financials 21.2.5.4. Sales Footprint 21.2.5.5. SWOT Analysis 21.2.5.6. Key Developments 21.2.5.7. Strategy Overview 21.2.5.7.1. Channel Strategy 21.2.5.7.2. Marketing Strategy 21.2.5.7.3. Product Strategy 21.2.6. Bio-Rad Laboratories, Inc. 21.2.6.1. Overview 21.2.6.2. Product Portfolio 21.2.6.3. Key Financials 21.2.6.4. Sales Footprint 21.2.6.5. SWOT Analysis 21.2.6.6. Key Developments 21.2.6.7. Strategy Overview 21.2.6.7.1. Channel Strategy 21.2.6.7.2. Marketing Strategy 21.2.6.7.3. Product Strategy 21.2.7. Thermo Fisher Scientific Inc. 21.2.7.1. Overview 21.2.7.2. Product Portfolio 21.2.7.3. Key Financials 21.2.7.4. Sales Footprint 21.2.7.5. SWOT Analysis 21.2.7.6. Key Developments 21.2.7.7. Strategy Overview 21.2.7.7.1. Channel Strategy 21.2.7.7.2. Marketing Strategy 21.2.7.7.3. Product Strategy 21.2.8. Promega Corporation 21.2.8.1. Overview 21.2.8.2. Product Portfolio 21.2.8.3. Key Financials 21.2.8.4. Sales Footprint 21.2.8.5. SWOT Analysis 21.2.8.6. Key Developments 21.2.8.7. Strategy Overview 21.2.8.7.1. Channel Strategy 21.2.8.7.2. Marketing Strategy 21.2.8.7.3. Product Strategy 21.2.9. Sysmex Inostics Inc. 21.2.9.1. Overview 21.2.9.2. Product Portfolio 21.2.9.3. Key Financials 21.2.9.4. Sales Footprint 21.2.9.5. SWOT Analysis 21.2.9.6. Key Developments 21.2.9.7. Strategy Overview 21.2.9.7.1. Channel Strategy 21.2.9.7.2. Marketing Strategy 21.2.9.7.3. Product Strategy 21.2.10. Danaher (Cepheid) 21.2.10.1. Overview 21.2.10.2. Product Portfolio 21.2.10.3. Key Financials 21.2.10.4. Sales Footprint 21.2.10.5. SWOT Analysis 21.2.10.6. Key Developments 21.2.10.7. Strategy Overview 21.2.10.7.1. Channel Strategy 21.2.10.7.2. Marketing Strategy 21.2.10.7.3. Product Strategy 21.2.11. FUJIREBIO 21.2.11.1. Overview 21.2.11.2. Product Portfolio 21.2.11.3. Key Financials 21.2.11.4. Sales Footprint 21.2.11.5. SWOT Analysis 21.2.11.6. Key Developments 21.2.11.7. Strategy Overview 21.2.11.7.1. Channel Strategy 21.2.11.7.2. Marketing Strategy 21.2.11.7.3. Product Strategy 21.2.12. Everlywell, Inc. 21.2.12.1. Overview 21.2.12.2. Product Portfolio 21.2.12.3. Key Financials 21.2.12.4. Sales Footprint 21.2.12.5. SWOT Analysis 21.2.12.6. Key Developments 21.2.12.7. Strategy Overview 21.2.12.7.1. Channel Strategy 21.2.12.7.2. Marketing Strategy 21.2.12.7.3. Product Strategy 21.2.13. Sansure Biotech Inc. 21.2.13.1. Overview 21.2.13.2. Product Portfolio 21.2.13.3. Key Financials 21.2.13.4. Sales Footprint 21.2.13.5. SWOT Analysis 21.2.13.6. Key Developments 21.2.13.7. Strategy Overview 21.2.13.7.1. Channel Strategy 21.2.13.7.2. Marketing Strategy 21.2.13.7.3. Product Strategy 22. Assumptions and Acronyms Used 23. Research Methodology
Explore Healthcare Insights
View Reports
Cervical Cancer Screening Market
